FY2025 · ended Dec 31, 2025 · Revenue $742.90M, -28.8% YoY · Filed Feb 27, 2026
Emergent Biosolutions Inc. (EBS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $742.9 million and net income of $52.6 million. Free cash flow was $156.8 million. As of Sep 30, 2026 it held $175.7 million in cash and investments and $520.3 million in total debt.
Revenue (TTM)
$649.10M
-17.7% vs year-ago TTM
Net income (TTM)
$-260.70M
-443.5% vs year-ago TTM
Operating cash flow (TTM)
$200.10M
+1439.2% vs year-ago TTM
Free cash flow (TTM)
$188.40M
+13357.1% vs year-ago TTM
EPS (TTM)
$-4.93
-464.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
51.77M
-4.7% vs prior year
Net cash
$-344.60M
as of Sep 30, 2026
Operating margin
-27.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EBS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Gaithersburg, MD
- SEC filer status
- Accelerated filer
- SEC CIK
- 1367644
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $742.9M | $1.0B | $1.0B | $1.1B | $1.8B |
| Operating income | $100.1M | -$108.7M | -$726.4M | -$170.0M | $341.4M |
| Net income | $52.6M | -$190.6M | -$760.5M | -$211.6M | $219.5M |
| Diluted EPS | $0.93 | -$3.60 | -$14.85 | -$4.22 | $4.06 |
| Operating cash flow | $170.6M | $58.7M | -$206.3M | -$34.1M | $320.2M |
| Free cash flow | $156.8M | $35.8M | -$257.9M | -$149.9M | $96.1M |
| Total assets | $1.3B | $1.4B | $1.8B | $3.2B | $3.0B |
| Total liabilities | $796.0M | $906.9M | $1.2B | $1.8B | $1.3B |
| Stockholders' equity | $522.6M | $482.8M | $649.3M | $1.4B | $1.6B |
| Cash and investments | $205.4M | $99.5M | $111.7M | $642.6M | $576.1M |
| Total debt | $601.3M | $712.4M | $885.7M | $1.4B | $879.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 16, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 1, 2026 | Aug 18, 2026 |
All 1001 Emergent Biosolutions Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.